MX2014005433A - Métodos y composiciones para modular bacterias gastrointestinales para promover la salud. - Google Patents

Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.

Info

Publication number
MX2014005433A
MX2014005433A MX2014005433A MX2014005433A MX2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A
Authority
MX
Mexico
Prior art keywords
proportion
compositions
composition
methods
disease
Prior art date
Application number
MX2014005433A
Other languages
English (en)
Inventor
Thomas W Boileau
Jennifer Brulc
Ravindranath Sreedhar Menon
Original Assignee
Gen Mills Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Mills Inc filed Critical Gen Mills Inc
Publication of MX2014005433A publication Critical patent/MX2014005433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Métodos y composiciones para tratar condiciones médicas o mejorar la salud en donde la composición se ingiere en una cantidad suficiente para modificar la proporción de las bacterias en un microbioma intestinal del individuo que ingiere la composición. La composición puede comprender polidextrosa o fibra de maíz soluble, por ejemplo. La proporción de Coriobacteriaceae se puede reducir pata tratar condiciones tales como triglicéridos en el suero elevados, enfermedad de hígado graso no alcohólico, síndrome metabólico, obesidad, o diabetes tipo 2. La proporción de Veillonellaceae se puede incrementar para reducir el colesterol en el suero. La proporción de Faecalibacterium se puede incrementar para tratar la enfermedad intestinal inflamatoria o la enfermedad de Crohn.
MX2014005433A 2011-11-04 2012-11-01 Métodos y composiciones para modular bacterias gastrointestinales para promover la salud. MX2014005433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555800P 2011-11-04 2011-11-04
PCT/US2012/063008 WO2013067146A1 (en) 2011-11-04 2012-11-01 Methods and compositions for modulating gastrointestinal bacteria to promote health

Publications (1)

Publication Number Publication Date
MX2014005433A true MX2014005433A (es) 2014-08-22

Family

ID=48192757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005433A MX2014005433A (es) 2011-11-04 2012-11-01 Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.

Country Status (11)

Country Link
US (1) US20150209383A1 (es)
EP (1) EP2773357A4 (es)
JP (1) JP2014532710A (es)
KR (1) KR20140093252A (es)
CN (1) CN104159588A (es)
AU (1) AU2012332491A1 (es)
BR (1) BR112014010660A2 (es)
CA (1) CA2854398A1 (es)
IN (1) IN2014CN04055A (es)
MX (1) MX2014005433A (es)
WO (1) WO2013067146A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3283087A4 (en) * 2015-04-14 2019-03-13 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
JP6573639B2 (ja) * 2016-01-26 2019-09-11 富士フイルム株式会社 腸内細菌数抑制剤、食品、及び医薬品
WO2017159647A1 (ja) * 2016-03-14 2017-09-21 物産フードサイエンス株式会社 フィーカリバクテリウム属細菌増殖剤
EP3511406A4 (en) * 2016-09-06 2020-04-01 BGI Shenzhen FAECALIBACTERIUM LONGUM AND ASSOCIATED APPLICATION
KR20200010450A (ko) 2017-06-02 2020-01-30 굿것 에스.엘. 장내 세균 불균형의 치료에 사용하기 위한 포도 껍질
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3466417A1 (en) * 2017-10-04 2019-04-10 Sorbonne Université Compounds for the prevention and treatment of glucose intolerance related conditions and obesity
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
CN109998112B (zh) * 2017-12-22 2024-05-14 奥地利商艾尔柏有限公司 红蝽杆菌纲促进肠道健康的用途
EP3752167A1 (en) * 2018-02-14 2020-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Polydextrose for the treatment of inflammatory diseases
WO2019216815A1 (en) * 2018-05-09 2019-11-14 Carbiotix Ab Method for measuring and improving gut health
CN112218646B (zh) * 2018-05-31 2024-06-11 深圳华大生命科学研究院 一种组合物及其应用
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
CA3153884A1 (en) * 2019-10-07 2021-04-15 Nikole KIMES Therapeutic pharmaceutical compositions
KR102174095B1 (ko) * 2019-12-11 2020-11-05 주식회사 에이치이엠 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
EP4333644A1 (en) * 2021-05-06 2024-03-13 Société des Produits Nestlé S.A. Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0394655A (ja) * 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd 栄養補給用組成物
JP4328473B2 (ja) * 2001-04-09 2009-09-09 雪印乳業株式会社 肥満予防改善飲食品
FI20020078A (fi) * 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
JP2003334025A (ja) * 2002-05-15 2003-11-25 Toyo Shinyaku:Kk 健康食品
DE60330781D1 (de) * 2002-08-06 2010-02-11 Danisco Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen
GB0302872D0 (en) * 2003-02-10 2003-03-12 Univ Liverpool Treatment of inflammatory bowel disease
AU2008256938B2 (en) * 2007-05-23 2013-02-28 Tate & Lyle Ingredients Americas Llc Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition
GB0903016D0 (en) * 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
JP6077303B2 (ja) * 2009-05-07 2017-02-08 タト エ リル アングルディアント フランス ソシエテ パ アクシオンス シンプリフィエ アルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランを含有する組成物及びアルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランの製造方法

Also Published As

Publication number Publication date
IN2014CN04055A (es) 2015-10-23
CA2854398A1 (en) 2013-05-10
WO2013067146A1 (en) 2013-05-10
AU2012332491A1 (en) 2014-05-29
EP2773357A4 (en) 2015-08-26
BR112014010660A2 (pt) 2017-05-09
US20150209383A1 (en) 2015-07-30
KR20140093252A (ko) 2014-07-25
JP2014532710A (ja) 2014-12-08
EP2773357A1 (en) 2014-09-10
CN104159588A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
MX2014005433A (es) Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.
Li et al. Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice
Xu et al. Function of Akkermansia muciniphila in obesity: interactions with lipid metabolism, immune response and gut systems
Quezada et al. Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics
Li et al. Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota
Zeng et al. Lotus seed resistant starch regulates gut microbiota and increases short-chain fatty acids production and mineral absorption in mice
Zou et al. Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice
Zhang et al. Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha
Liu et al. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice
Kondo et al. Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation
Song et al. Dietary anthocyanin-rich extract of açai protects from diet-induced obesity, liver steatosis, and insulin resistance with modulation of gut microbiota in mice
Liu et al. Gut microbiota: A new target for T2DM prevention and treatment
MX2012012777A (es) Agentes de union del receptor nuclear.
EP2201370A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES
Zhou et al. Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring
Kobyliak et al. Comparative experimental investigation on the efficacy of mono-and multiprobiotic strains in non-alcoholic fatty liver disease prevention
NZ602249A (en) Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
WO2010081079A3 (en) Composition and method for treatment of diabetes
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
Fabbiano et al. Host–microbiota mutualism in metabolic diseases
MX2012003459A (es) Composicion y metodo para el tratamiento de la diabetes.
Fan et al. Research progress of gut microbiota and obesity caused by high-fat diet
Hua et al. Ginseng soluble dietary fiber can regulate the intestinal flora structure, promote colon health, affect appetite and glucolipid metabolism in rats
RU2013128920A (ru) Способ ингибирования патогенов с использованием питательной композиции
WO2011087857A3 (en) Compositions and methods for treating obesity and diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal